ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.

Jeroen H J Paulissen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.